Company Overview

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) is a commercial-stage biotechnology company founded in 1989 and headquartered in Carlsbad, California, that provides RNA-targeted medicines in the United States. The company is the leading developer of antisense technology to discover and develop novel drugs, with its broad clinical and preclinical pipeline targeting a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases.

Financial Performance

As of September 2025, Ionis has a market capitalization of approximately $9.8 billion with 159.39 million shares outstanding. For the full year 2024, the company reported total revenue of $705 million, representing an 11% decrease from the previous year but exceeding expectations. The company's revenue for the last quarter amounts to $452 million, significantly beating the estimated figure of $298.30 million.

Key Financial Highlights:

• Management has provided 2025 revenue guidance exceeding $600 million

• Net income for the last quarter was $123.55 million, compared to -$146.94 million in the previous quarter, representing a 184.08% improvement

• In September 2024, Ionis raised $500 million from a public offering of its common stock

Commercial Products and Recent FDA Approvals

TRYNGOLZA™ (olezarsen)

TRYNGOLZA™ was approved by the U.S. Food and Drug Administration as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), making it the first approved treatment for FCS in the United States. The drug marks Ionis' first wholly-owned drug and first independent commercial launch, launched in December 2024. TRYNGOLZA™ has also received European Union approval for FCS treatment.

DAWNZERA™ (donidalorsen)

In August 2025, the FDA approved DAWNZERA™ for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older, making it the first and only RNA-targeted medicine approved for HAE. Phase 3 results showed that monthly attack rates were 81% lower with every four-week dosing and 55% lower with every-other-month dosing compared to placebo. This represents Ionis' second independent medicine approved in less than nine months.

WAINUA™ (eplontersen)

WAINUA™ is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults and was launched in the U.S. in collaboration with AstraZeneca. The drug was commercially launched in the United States in the first quarter of 2024.

Established Product Portfolio

Ionis' marketed medicines consist of TRYNGOLZA™, WAINUA™ (eplontersen), SPINRAZA® (nusinersen), QALSODY® (tofersen), TEGSEDI® (inotersen) and WAYLIVRA® (volanesorsen). Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).

Pipeline and Development Programs

The company's broad, diverse pipeline has more than 40 potential first-in-class and/or best-in-class medicines designed to treat a broad range of diseases. Key development programs include:

Phase 3 Programs

• Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD)

• Tryngolza is being evaluated for severe hypertriglyceridemia (sHTG) across three late-stage studies — CORE, CORE2 and ESSENCE, with data expected in the second half of 2025

• ION582 for Angelman syndrome with Phase 3 trial start planned in the first half of 2025

• Zilganerse for Alexander disease

Strategic Partnerships

The company has strategic collaboration with Biogen for the treatment of neurological disorders and collaboration and license agreements with GSK, AstraZeneca, Novartis, and Roche. These partnerships include collaboration deals with leading drugmakers/biotech companies such as AstraZeneca, Biogen, GSK plc and Novartis for developing and marketing its medicines.

Technology Platform

Ionis is a pioneer in developing RNA medicines called antisense oligonucleotides, and the company has long been known for partnering its products instead of commercializing them. The company's antisense technology platform has served as a springboard for drug discovery and realized hope for patients with unmet needs, with its broad clinical and preclinical pipeline targeting a wide variety of diseases with emphasis on cardiovascular, metabolic, neurological, and rare diseases.

Strategic Transformation

Under CEO Brett Monia, who became CEO in 2020, the company has changed course from its historical partnering approach to "fully maximize the value of our innovative medicine by retaining and delivering them directly to patients." Tryngolza is the first of four independent launches Ionis plans to conduct through 2027.

Future Outlook

TRYNGOLZA™ is the first of four independent Ionis product launches anticipated over the next three years, with the company also expecting four key launches from important partnered programs within this timeframe. The company's investments position Ionis to deliver substantial and growing product revenue, and when combined with increasing royalty revenue from anticipated partner launches, provides a clear path to achieve sustained positive cash flow.